A Combination of Cellular Biomarkers Predicts Failure to Respond to Rituximab in Rheumatoid Arthritis: A 24-Week Observational Study

Arthritis Research & Therapy
doi 10.1186/s13075-016-1091-1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Safety of Rituximab in Rheumatoid Arthritis

Reumatismo
Rheumatology
2011English

IgG Fc Galactosylation Predicts Response to Methotrexate in Early Rheumatoid Arthritis

Arthritis Research & Therapy
2017English

B Cells in Rheumatoid Arthritis: From Pathogenic Players to Disease Biomarkers

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2014English

Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study

PLoS ONE
Multidisciplinary
2016English

A Systems Approach to Rheumatoid Arthritis

PLoS ONE
Multidisciplinary
2012English

Step-Up Combination Versus Switching of Non-Biological Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: Results From a Retrospective Observational Study

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2007English

Rituximab Therapy in Greek Patients With Rheumatoid Arthritis

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

To: A 24-Week, Randomized, Double-Blind Study of Donepezil in Moderate to Severe Alzheimer's Disease

Neurology
Neurology
2001English

Rituximab Treatment in a Patient With Primary Biliary Cirrhosis and Rheumatoid Arthritis

Archives of Rheumatology
Rheumatology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy